Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.
Reardon D, Brem S, Desai A, Bagley S, Kurz S, De La Fuente M, Nagpal S, Welch M, Hormigo A, Forsyth P, Mandel J, Khagi S, Aiken R, Walbert T, Lieberman F, Portnow J, Battiste J, Gillespie E, Lowy I, Skolnik J. Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. Journal Of Clinical Oncology 2022, 40: 2004-2004. DOI: 10.1200/jco.2022.40.16_suppl.2004.Peer-Reviewed Original ResearchPre-treatment tissueCohort AT cellsLytic potentialAntigen-specific T cellsImmune responsePost-treatment tumor tissuesFlow cytometryMedian OS durationMGMT-unmethylated patientsPD-1 inhibitorsDiagnosed GBM patientsT cell infiltrationAdverse event profileImmune-related markersImmune cell markersRobust immune responseCellular immune responsesWilcoxon rank sum testImmune response suppressionGene expressionPresence of perforinGene expression signaturesRank sum testMedian OS